Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Halozyme Therapeutics, Inc. - Common Stock (NQ: HALO )

61.06 +0.17 (+0.28%)
Streaming Delayed Price Updated: 4:00 PM EDT, Mar 13, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 992,126
Open 60.77
Bid (Size) 61.00 (1)
Ask (Size) 63.00 (5)
Prev. Close 60.89
Today's Range 60.44 - 61.48
52wk Range 37.73 - 65.53
Shares Outstanding 142,334,900
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
HALOZYME THERAPEUTICS INC (NASDAQ:HALO) is a prime example of a stock that offers more than what meets the eye in terms of fundamentals.
HALOZYME THERAPEUTICS INC has a stellar value proposition. NASDAQ:HALO not only scores well in profitability, solvency, and liquidity but also maintains a very reasonable price point. 
Via Chartmill
HALOZYME THERAPEUTICS INC (NASDAQ:HALO) Technical Analysis observations.
Exploring HALOZYME THERAPEUTICS INC's Technical Signals and Breakout Potential: A technical analysis of HALOZYME THERAPEUTICS INC (NASDAQ:HALO) shows it may be setting up for a breakout. 
Via Chartmill

Performance

YTD
+27.18%
+27.18%
1 Month
+6.49%
+6.49%
3 Month
+28.85%
+28.85%
6 Month
+2.81%
+2.81%
1 Year
+45.55%
+45.55%

More News

Read More
NASDAQ:HALO: a strong growth stock preparing for the next leg up?.
Via Chartmill
Assessing Halozyme Therapeutics: Insights From 9 Financial Analysts
Via Benzinga
NASDAQ:HALO is not too expensive for the growth it is showing.
Via Chartmill
NASDAQ:HALO appears to be flying under the radar despite its strong fundamentals.
Via Chartmill
Demystifying Halozyme Therapeutics: Insights From 8 Analyst Reviews
Via Benzinga
Analyst Expectations For Halozyme Therapeutics's Future
Via Benzinga
9 Analysts Have This To Say About Halozyme Therapeutics
Via Benzinga
Earnings Scheduled For February 18, 2025
Via Benzinga
Is NASDAQ:HALO on the Verge of a Major Breakout as a Strong Growth Stock?
Via Chartmill
Looking for growth without the hefty price tag? Consider NASDAQ:HALO.
Via Chartmill
HALOZYME THERAPEUTICS INC (NASDAQ:HALO) is a candidate for high growth investors. Here's why.
Via Chartmill
NASDAQ:HALO—A High-Growth Stock Gearing Up for Its Next Upward Move.
Via Chartmill
In the world of growth stocks, NASDAQ:HALO shines as a value proposition.
Via Chartmill
In a market where value is scarce, NASDAQ:HALO offers a refreshing opportunity with its solid fundamentals.
Via Chartmill
BeiGene Stock Meets 80-Plus RS Rating Benchmark
Via Investor's Business Daily
BridgeBio Pharma Stock Earns 87 RS Rating
Via Investor's Business Daily
(HALO) - Analyzing Halozyme Therapeutics's Short Interest
Via Benzinga
SpringWorks Therapeutics Stock Gets A RS Rating Lift
Via Investor's Business Daily
Despite its growth, NASDAQ:HALO remains within the realm of affordability.
Via Chartmill
In a market where value is scarce, NASDAQ:HALO offers a refreshing opportunity with its solid fundamentals.
Via Chartmill
In a market where value is scarce, NASDAQ:HALO offers a refreshing opportunity with its solid fundamentals.
Via Chartmill
Halozyme Withdraws Evotec Bid After Rebuff, Reaffirms Strong Growth Outlook
Via Benzinga
While growth is established for NASDAQ:HALO, the stock's valuation remains reasonable.
Via Chartmill
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.